{"title":"Testosterone Replacement Therapy: A Narrative Review with a Focus on New Oral Formulations.","authors":"Salman Z Bhat, Adrian S Dobs","doi":"10.17925/EE.2022.18.2.133","DOIUrl":null,"url":null,"abstract":"<p><p>Male hypogonadism affects 10-30% of the male population and is often under-recognized and under-treated. Different replacement formulations exist, each with specific benefits and limitations. These replacements include gels, patches and short- and long-acting injectables. JATENZO® (oral testosterone undecanoate; Clarus Therapeutics Inc., Northbrook, IL, US) is the first oral formulation of testosterone approved by the US Food and Drug Administration. TLANDO® (oral testosterone undecanoate; Lipocine Inc., Salt Lake City, UT, US), another oral testosterone formulation, has also recently been approved by the US Food and Drug Administration. Based on unique chemistry using a self-emulsifying drug delivery system and lymphatic absorption, JATENZO and TLANDO address some of the limitations of other dosing routes while providing a safe option without evidence of liver dysfunction. This review discusses various testosterone treatment options, focusing on the role and pharmacokinetics of the new oral formulations.</p>","PeriodicalId":75231,"journal":{"name":"TouchREVIEWS in endocrinology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9835814/pdf/","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"TouchREVIEWS in endocrinology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.17925/EE.2022.18.2.133","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1
Abstract
Male hypogonadism affects 10-30% of the male population and is often under-recognized and under-treated. Different replacement formulations exist, each with specific benefits and limitations. These replacements include gels, patches and short- and long-acting injectables. JATENZO® (oral testosterone undecanoate; Clarus Therapeutics Inc., Northbrook, IL, US) is the first oral formulation of testosterone approved by the US Food and Drug Administration. TLANDO® (oral testosterone undecanoate; Lipocine Inc., Salt Lake City, UT, US), another oral testosterone formulation, has also recently been approved by the US Food and Drug Administration. Based on unique chemistry using a self-emulsifying drug delivery system and lymphatic absorption, JATENZO and TLANDO address some of the limitations of other dosing routes while providing a safe option without evidence of liver dysfunction. This review discusses various testosterone treatment options, focusing on the role and pharmacokinetics of the new oral formulations.
男性性腺功能减退影响10-30%的男性人口,但往往未得到充分认识和治疗。存在不同的替代配方,每种配方都有特定的优点和局限性。这些替代品包括凝胶、贴片和短效和长效注射剂。JATENZO®(口服十一酸睾酮;Clarus Therapeutics Inc., Northbrook, IL, US)是第一个获得美国食品和药物管理局批准的口服睾酮制剂。TLANDO®(口服十一酸睾酮;Lipocine Inc., Salt Lake City, UT, US)是另一种口服睾酮制剂,最近也获得了美国食品和药物管理局的批准。JATENZO和TLANDO基于独特的化学成分,利用自乳化药物输送系统和淋巴吸收,解决了其他给药途径的一些局限性,同时提供了一种安全的选择,没有肝功能障碍的证据。这篇综述讨论了各种睾酮治疗方案,重点是新的口服制剂的作用和药代动力学。